Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Difference of Stroke Subtype Under Anticoagulation Therapy between Direct Oral Anticoagulant (DOAC) Only and DOAC Plus Antiplatelet Agent
Cerebrovascular Disease and Interventional Neurology
P5 - Poster Session 5 (8:00 AM-9:00 AM)
4-008
To investigate whether there is any difference of stroke pathogenesis in patients under anticoagulation therapy between direct oral anticoagulant agent (DOAC) only and DOAC plus antiplatelet agent.

As pleiotropic effect of direct oral anticoagulants (DOACs), antiplatelet effect and anti-inflammatory effect have been reported. While, no significant difference was observed between DOACs and aspirin in secondary prevention of the embolic stroke of undetermined source (ESUS) trials.

Following the ethical committee of the hospital, acute ischemic stroke patients were screened between April 2015 and March 2019, and patients who had taken DOAC prior to the index stroke were included in this study (n=64, 77.4±8.0 years old). Patient’s characteristics and stroke subtypes were assessed on the clinical record. All patients were classified into DOAC only (n=56) and DOAC plus antiplatelet medicine (DOAC+AP: n=8) groups.
Frequency of diabetes mellitus was significantly higher in DOAC+AP group compared with DOAC only group (p=0.044: 62% and 25%, respectively). Secondary prevention was more prevalent in DOAC+AP group compared with DOAC only group (p=0.053: 88% and 43%, respectively). DOAC+AP group showed lower percentage of cardiogenic embolism (CE) compared with DOAC only group (p=0.053: 25% and 66%, respectively). Even more, patients in DOAC+AP group showed lower percentage of CE compared with patients with several atherosclerotic risks in DOAC only group (p=0.114: 25% and 61%, respectively). ESUS was not observed in DOAC+AP group, although 4 ESUS patients (11%) were found in those patients of DOAC only group.

DOAC plus antiplatelet medicine might be able to reduce the risk of cardiogenic embolism and ESUS in patients with several atherosclerotic risks who are required anticoagulation.

Authors/Disclosures
Taizen Nakase (Research Institute for Brain & Blood Vessels -Akita)
PRESENTER 		Taizen Nakase has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file